beneficiary 1 : istituto di ricerche farmacologiche mario negri
DESCRIPTION
Beneficiary 1 : Istituto di Ricerche Farmacologiche Mario Negri Beneficiary 2 : Istituto Superiore di Sanità Beneficiary 3 : Federazione Nazionale dell’Industria Chimica Beneficiary 4 : Politecnico di Milano, Dipartimento di Elettronica e Informazione - PowerPoint PPT PresentationTRANSCRIPT
May 2012 1
May 2012 2
Beneficiary 1 : Istituto di Ricerche Farmacologiche Mario Negri
Beneficiary 2 : Istituto Superiore di Sanità
Beneficiary 3 : Federazione Nazionale dell’Industria Chimica
Beneficiary 4 : Politecnico di Milano, Dipartimento di Elettronica e Informazione
Beneficiary 5 :KnowledgeMiner Software Frank Lemke
May 2012 3
Promotion of non testingmethods (NTM) fortheiruse in the REACH contextlinkingscientists,
regulators and industries
toevaluate and validateexisting NTM fortheirapplicationaccordingto REACH needs
May 2012 4
REACH &REACH &IINNOVATIONNNOVATION
REACHpromotesInnovation(Article 1)
QSAR ismentioned
AllInfo should be used
May 2012 5
= f ( )
May 2012 6
Survey of current methods for the compliance to the REACH legislation
Identification of the criteria for the non-testing methods for the REACH legislation
Identification of suitable experimental databases/data sets for the ecotoxicological, toxicological and environmental endpoints for REACH
List of (Q)SAR models for the ecotoxicological, toxicological and environmental endpoints for REACH, and their review
Validation of non-testing methods (incl. read-across)
Identification of boundaries for best use of models (applicability domain) and of the assessment factors
May 2012 7
Architecture for integration of different non-testing methods for best performances and coverage of applicability
Communication and dissemination initiatives
Web portal
Project management
Monitoring
Audit
After-LIFE Communication plan
May 2012 8
EndpointsproducedforREACH byLaboratories
May 2012 9
Global Predictions on the 1544 compounds (CPDB+Leadscope) of the seven programs examined
May 2012 10
BCF – Best Models based on R2 and AccuracyOrdered by R2
May 2012 11
May 2012 12
IN SELECTED CASES NON-TESTING METHODS CAN BE USED:
BEST MODELS: mutagenicity, BCF;
CRITICAL MODELS: daphnia, carcinogenicity;
Important to consider the applicability domain;
Important the correct evaluation of the results (expert);
USE of more than one model preferable.